參考文獻 |
(1) Taiwan News (臺灣英文新聞). 193 tons of Prescription Medication are Thrown Away in Taiwan per Year https://www.taiwannews.com.tw/en/news/3437177 (accessed Jun 20, 2018).
(2) US Drug Enforcement Agency. DEA Brings in Record Number of Unused Pills During 15th Annual National Prescription Drug Take Back Day https://www.dea.gov/divisions/hq/2018/hq050718.shtml (accessed Apr 22, 2018).
(3) Law, A. V.; Sakharkar, P.; Zargarzadeh, A.; Tai, B. W. B.; Hess, K.; Hata, M.; Mireles, R.; Ha, C.; Park, T. J. Taking Stock of Medication Wastage: Unused Medications in US Households. Res. Soc. Adm. Pharm. 2015, 11 (4), 571–578.
(4) Zargazadeh, A. H.; Tavakoli, N.; Hassanzadeh, A. A Survey on the Extent of Medication Storage and Wastage in Urban Iranian Households. Clin. Ther. 2005, 27 (6), 960–969.
(5) Abou-Auda, H. S. An Economic Assessment of the Extent of Medication Use and Wastage Among Families in Saudi Arabia and Arabian Gulf Countries. Clin. Ther. 2003, 25 (4), 1276–1292.
(6) Daughton, C. G. Drugs and the Environment?: Stewardship & Sustainability; Las Vegas, NV, 2010.
(7) Gray, R. C. F.; Hogerzeil, H. V.; Pruss, A. M.; Rushbrook, P. Guideline of Safe Disposal of Unused Pharmaceuticals in and After Emergencies; Geneva, 1999.
(8) Bero, L.; Carson, B.; Moller, H.; Hill, S. To Give is Better Than to Receive: Compliance with WHO Guidelines for Drug Donations during 2000-2008. Bull. World Health Organ. 2010, 88 (12), 922–929.
(9) Benaragama; Fernandopulle, R. The Expectations, The Reality and The Burden of Drug Donations; Colombo, 2010.
(10) Berckmans, P.; Dawans, V.; Schmets, G.; Vandenbergh, D.; Autier, P. Inappropriate Drug-Donation Practices In Bosnia and Herzegovina, 1992 to 1996. N. Engl. J. Med. 1997, 337 (December 18), 1839–1845.
(11) Pharmaciens Sans Frontieres Comite International. Study on Drug Donations in the Province of Aceh in Indonesia; Bordeaux, 2005.
(12) Agence France-Presse. In Indonesia, a Tsunami of Useless edicines http://www.terradaily.com/2006/060728020734.9kesgdli.html (accessed May 31, 2018).
(13) Hairapetian, A.; Alexanian, A.; Ferir, M. C.; Agoudjian, V.; Schmets, G.; Dallemagne, G.; Leva, M. N.; Pinel, J.; Autier, P. Drug Supply in the Aftermath of the 1988 Armenian Earthquake. Lancet 1990, 335 (8702), 1388–1390.
(14) Ali, H. M.; Homeida, M. M. A.; Abdeen, M. A. E. R. “Drug Dumping” in Donations to Sudan. Lancet 1988, March 5 (1(8584)), 538–539.
(15) Offerhaus, L. Russia: Emergency Drugs Aid Goes Awry. Lancet 1992, 339 (March 7), 607.
(16) Wallerstein, C. Unusable Medicines “Dumped” on Venezuela. BMJ 2000, 320 (June), 1491.
(17) Pomerantz, J. M. Recycling Expensive Medication: Why Not?? MedGenMed 2004, 6 (2), 1–10.
(18) Allen, M. Wasted Medicine: America’s Other Drug Problem. ProPublica. New York April 27, 2017.
(19) Glassmeyer, S. T.; Hinchey, E. K.; Boehme, S. E.; Daughton, C. G.; Ruhoy, I. S.; Conerly, O.; Daniels, R. L.; Lauer, L.; Mccarthy, M.; Nettesheim, T. G.; et al. Disposal Practices for Unwanted Residential Medications in the United States. Environ. Int. 2009, 35 (3), 566–572.
(20) Mceachran, A. D.; Shea, D.; Bodnar, W.; Nichols, E. G. Pharmaceutical Occurrence in Groundwater and Surface Waters in Forests Land-Applied with Municipal Wastewater. Environ. Toxicol. Chem. 2016, 35 (4), 898–905.
(21) Deo, R. P. Pharmaceuticals in the Surface Water of the USA: A Review. Curr. Environ. Heal. Reports 2014, 1 (2), 113–122.
(22) Chevre, N. Pharmaceuticals in Surface Waters: Sources, Behavior, Ecological Risk, and Possible Solutions. Case Study of Lake Geneva, Switzerland. Wiley Interdiscip. Rev. Water 2014, 1 (1), 69–86.
(23) Glassmeyer, S.; Furlong, E.; Kolpin, D.; Cahill, J.; Zaugg, S. Transport of Chemical and Microbial Compounds from Known Wastewater Discharges?: Potential for Use as Indicators of Human Fecal Contamination. 2005, 5157–5169.
(24) Ashton, D.; Hilton, M.; Thomas, K. V. Investigating the Environmental Transport of Human Pharmaceuticals to Streams in the United Kingdom. Sci. Total Environ. 2004, 333 (1–3), 167–184.
(25) Batt, A. L.; Bruce, I. B.; Aga, D. S. Evaluating the Vulnerability of Surface Waters to Antibiotic Contamination from Varying Wastewater Treatment Plant Discharges. Environ. Pollut. 2006, 142 (2), 295–302.
(26) Fram, M. S.; Belitz, K. Occurrence and Concentrations of Pharmaceutical Compounds in Groundwater Used for Public Drinking-Water Supply in California. Sci. Total Environ. 2011, 409 (18), 3409–3417.
(27) Scheytt, T.; Mersmann, P.; Leidig, M.; Pekdeger, A.; Heberer, T. Transport of Pharmaceutically Active Compounds in Saturated Laboratory Columns. Ground Water 2004, 42 (5), 767–773.
(28) Verstraeten, I. M.; Fetterman, G. S.; Meyer, M. J.; Bullen, T.; Sebree, S. K. Use of Tracers and Isotopes to Evaluate Vulnerability of Water in Domestic Wells to Septic Waste. Gr. Water Monit. Remediat. 2005, 25 (2), 107–117.
(29) Stackelberg, P. E.; Gibs, J.; Furlong, E. T.; Meyer, M. T.; Zaugg, S. D.; Lippincott, R. L. Efficiency of Conventional Drinking-Water-Treatment Processes in Removal of Pharmaceuticals and Other Organic Compounds. Sci. Total Environ. 2007, 377 (2–3), 255–272.
(30) Kummerer, K. Drugs in the Environment: Emission of Drugs, Diagnostic Aids and Disinfectants into Wastewater by Hospitals in Relation to Other Sources - A Review. Chemosphere 2001, 45 (6–7), 957–969.
(31) Popken, B. Patients Beg For Pricey Drugs On Facebook Black Market https://www.nbcnews.com/business/consumer/patients-beg-pricey-drugs-facebook-black-market-n754266 (accessed Jun 7, 2018).
(32) Penjual Obat di Pasar 16 Ilir Ini Beli Obat Bekas dari Sembarang Orang, Faktanya http://palembang.tribunnews.com/2017/10/02/penjual-obat-di-pasar-16-ilir-ini-beli-obat-bekas-dari-sembarang-orang-faktanya (accessed Jun 7, 2018).
(33) Allen, M. That Drug Expiration Date May Be More Myth Than Fact. ProPublica. New York July 18, 2017.
(34) Cantrell, L.; Suchard, J. R.; Wu, A.; Gerona, R. R. Stability of Active Ingredients in Long-Expired Prescription Medications. ArchInternMed 2012, 172 (21), 1685–1687.
(35) Lyon, R. C.; Taylor, J. E. B. S.; Porter, D. A.; Prasanna, H. R.; Hussain, A. S. Stability Profiles of Drug Products Extended beyond Labeled Expiration Dates. J. Pharm. Sci. 2006, 95 (7), 1549–1560.
(36) Cantrell, L.; Cantrell, P.; Wen, A.; Gerona, R. R. Epinephrine Concentrations in EpiPens After the Expiration Date. Ann. Intern. Med. 2017, 166 (12), 918–919.
(37) U.S. Food and Drug Administration. Don’t Be Tempted to Use Expired Medicines https://www.fda.gov/Drugs/ResourcesForYou/SpecialFeatures/ucm481139.htm (accessed Feb 22, 2018).
(38) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Guidance for Industry; 2016.
(39) Transparency Market Research. Active Pharmaceutical Ingredients Market to be worth 219.60 Billion USD by 2023?: TMR https://globenewswire.com/news-release/2016/09/20/873069/0/en/Active-Pharmaceutical-Ingredients-Market-to-be-worth-219-60-Billion-USD-by-2023-TMR.html (accessed Jun 5, 2018).
(40) Rainsford, K. D. Fifty Years Since the Discovery of Ibuprofen. Inflammopharmacology 2011, 19 (6), 293–297.
(41) Front Research. Global Ibuprofen Demand to Grow Stably in Upcoming Years http://www.frontresearch.com/news/global-ibuprofen-demand-to-grow-stably-in-upcoming-years/ (accessed Feb 28, 2018).
(42) Herzfeldt, C. D.; Kummel, R. Dissociation Constants, Solubilities and Dissolution Rates of Some Selected Nonsteroidal Antiinflammatories. Drug Dev. Ind. Pharm. 1983, 9 (5), 767–793.
(43) Potthast, H.; Dressman, J. B.; Junginger, H. E.; Midha, K. K.; Oeser, H.; Shah, V. P.; Vogelpoel, H.; Barends, D. M. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ibuprofen. J. Pharm. Sci. 2005, 94 (10), 2121–2131.
(44) Dudognon, E.; Danede, F.; Descamps, M.; Correia, N. T. Evidence for a New Crystalline Phase of Racemic Ibuprofen. Pharm. Res. 2008, 25 (12), 2853–2858.
(45) Derollez, P.; Dudognon, E.; Affouard, F.; Danede, F.; Correia, N. T.; Descamps, M. Ab initio structure determination of phase II of racemic ibuprofen by X-ray powder diffraction. Acta Crystallogr. Sect. B Struct. Sci. 2010, 66 (1), 76–80.
(46) Armitage, B. J.; Lampard, J. F.; Smith, A. Composition of S-Sodium Ibuprofen. U.S. Patent No. 6,242,000 B1, 2001.
(47) Bruzzese, T.; Ferrari, R. Method of Relieving Pain and Treating Inflammatory Conditions in Warm-Blooded Animals. U.S. Patent No. 4,279,926, 1981.
(48) Lee, T.; Wang, Y. W. Initial Salt Screening Procedures for Manufacturing Ibuprofen. Drug Dev. Ind. Pharm. 2009, 35 (5), 555–567.
(49) Lee, T.; Kuo, C. S.; Chen, Y. H. Solubility, Polymorphism, Crystallinity, and Crystal Habit of Acetaminophen and Ibuprofen by Initial Solvent Screening. Pharm. Technol. 2006, 30 (10), 72–87.
(50) Atkinson, H. C. Pharmaceutical Composition of Ibuprofen and Paracetamol and Methods of Using the Same. U.S. Patent Application No. 2011/0275718 A1, 2011.
(51) Tidmarsh, G.; Golombik, B. L.; Sharma, P. Methods and Medicaments for Administration of Ibuprofen. U.S. Patent Application No. 2008/0021078 A1, 2018.
(52) Elango, V.; Murphy, M. A.; Smith, B. L.; Davenport, K. G.; Mott, G. N.; Moss, G. L. Method for Producing Ibuprofen. U.S. Patent No. 4,981,995, 1991.
(53) Cann, M. C.; Connelly, M. E. The BHC Company Synthesis of Ibuprofen: A Greener Synthesis of Ibuprofen Which Creates Less Waste and Fewer Byproducts. In Real World Cases in Green Chemistry; American Chemical Society: Washington DC, 2000; pp 19–24.
(54) Yamashita, S.; Matsuzawa, Y. Where are We with Probucol: A New Life for an Old Drug? Atherosclerosis 2009, 207 (1), 16–23.
(55) Barnhart, J. W.; Sefranka, J. A.; McIntosh, D. D. Hypocholesterolemic Effect of 4,4’-(Isopropylidenedithio)-Bis(2,6-di-t-Butylphenol) (Probucol). Am. J. Clin. Nutr. 1970, 23 (9), 1229–1233.
(56) Yamashita, S.; Masuda, D.; Matsuzawa, Y. Did We Abandon Probucol Too Soon? Curr. Opin. Lipidol. 2015, 26 (4), 304–316.
(57) ThePharmaLetter. Hoechst Marion Roussel Pulls Probucol from US Market https://www.thepharmaletter.com/article/hoechst-marion-roussel-pulls-probucol-from-us-market (accessed Apr 3, 2018).
(58) Gerber, J. J.; Caira, M. R.; Lotter, A. P. Structures of Two Conformational Polymorphs of the Cholesterol-Lowering Drug Probucol. J. Crystallogr. Spectrosc. Res. 1993, 23 (11), 863–869.
(59) Merck Index, 11th ed.; Budavari, S., Ed.; Merck and Co. Inc.: Rahway, New Jersey, 1989.
(60) Giordano, C.; Barreca, G. Process for Preparing an Intermediate Useful In the Synthesis of Probucol. U.S. Patent No. 5,157,156, 1992.
(61) Chaudhari, S. P.; Patil, P. S. Pharmaceutical Excipients?: A Review. Int. J. Adv. Pharmacy, Biol. Chem. 2012, 1 (1), 21–34.
(62) Haywood, A.; Glass, B. Pharmaceutical Excipients – Where do We Begin? Aust. Prescr. 2011, 34 (4), 112–114.
(63) International Excipients Certification. International Excipients Certification Project: Minimize Risks – Maximize Benefits; London, 2009.
(64) Atwood, J. L. Separation of Active Pharmaceutical Ingredients (APIs) from Excipients in Pharmaceutical Formulations. Cryst. Growth Des. 2015, 15 (6), 2874–2877.
(65) Atwood, J. L. Separation Method for Active Pharmaceutical Ingredients from Excipients. U.S. Patent Application No. 2016/0340350 A1, 2016.
(66) Hsieh, D. S.; Lindrud, M.; Lu, X.; Zordan, C.; Tang, L.; Davies, M. A Process for Active Pharmaceutical Ingredient Recovery from Tablets Using Green Engineering Technology. Org. Process Res. Dev. 2017, 21, 1272–1285.
(67) Geankoplis, C. J. Transport Processes and Unit Operations, 3rd ed.; Prentice-Hall, 1993.
(68) McCabe, W. L.; Smith, J. C.; Harriott, P. Unit Operations of Chemical Engineering, 5th ed.; McGraw Hill Co.: Singapore, 1993.
(69) Frey, E.; Slater, C. S.; Savelski, M. J.; Hesketh., R. P. Selection and Reduction of Organic Solvents in the Pharmaceutical Industry. In Paper 17 presented at the American Chemical Society 10th Green Chemistry and Engineering Conference; Washington, 2006.
(70) Grodowska, K.; Parczewski, A. Organic Solvents in the Pharmaceutical Industry. Acta Pol. Pharm. 2010, 67 (1), 3–12.
(71) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q3C: Impurities: Guideline for Residual Solvents. 2016.
(72) Sasmal, B. K.; Billa, P. R.; Nasare, V. D.; Mohan, M. S.; Jayanthi, S.; Dubey, R.; Avvaru, S.; Satti, P. R.; Manas, R. M.; Chidipothu, A.; et al. Fixed Dose Drug Combination Formulations. U.S. Patent Application No. 2012/0045505 A1, 2012.
(73) Parikh, S. J.; Chorover, J. FTIR Spectroscopic Study of Biogenic Mn-Oxide Formation by Pseudomonas putida GB-1. Geomicrobiol. J. 2005, 22 (5), 207–218.
(74) Chen, Y.; Zou, C.; Mastalerz, M.; Hu, S.; Gasaway, C.; Tao, X. Applications of Micro-Fourier Transform Infrared Spectroscopy (FTIR) in the Geological Sciences—A Review. Int. J. Mol. Sci. 2015, 16 (12), 30223–30250.
(75) Farkas, S. Z.; Imre, S.; Muntean, D. L.; Tero-Vescan, A. Analysis of Drug Related Impurities by Infrared Spectrometry in the Class of Statins. Farmacia 2013, 61 (6), 1091–1101.
(76) Randall, C.; Rocco, W. L.; Ricou, P. XRD in Pharmaceutical Analysis?: A Versatile Tool for Problem-Solving. Am. Pharm. Rev. 2010, 13 (6), 52–59.
(77) Anderson, R. J.; Bendell, D. J.; Groundwater, P. W. Organic Spectroscopic Analysis; The Royal Society of Chemistry: Cambridge, 2004; Vol. 22.
(78) Lim, J. S.; Choi, H.; Lim, I. S.; Park, S. B.; Lee, Y. S.; Kim, S. K. Photodissociation Dynamics of Thiophenol-d1: The Nature of Excited Electronic States Along the s-d Bond Dissociation Coordinate. J. Phys. Chem. A 2009, 113 (39), 10410–10416.
(79) Zhang, L.; Zhou, S.; Wang, S.; Wang, L.; Li, J. Surfactant Surface Tension Effects on Promoting Hydrate Formation: An Experimental Study Using Fluorocarbon Surfactant (Intechem-01) + SDS Composite Surfactant. J. Environ. Prot. (Irvine,. Calif). 2013, 04 (05), 42–48.
(80) Lu, J.; Wang, X. J.; Yang, X.; Ching, C. B. Polymorphism and Crystallization of Famotidine. Cryst. Growth Des. 2007, 7 (9), 1590–1598.
(81) Jones, H. P.; Davey, R. J.; Cox, B. G. Crystallization of a Salt of a Weak Organic Acid and Base: Solubility Relations, Supersaturation Control and Polymorphic Behavior. J. Phys. Chem. B 2005, 109 (11), 5273–5278.
(82) Beckmann, W. Seeding the Desired Polymorph: Background, Possibilities, Limitations, and Case Studies. Org. Process Res. Dev. 2000, 4 (5), 372–383.
(83) Pavia, D. L.; Lampman, G. M.; Kriz, G. S. Introduction to Spectroscopy, 3rd ed.; Thomson Learning, Inc.: Bellingham, 2001. |